Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects
Authors:
- 12 March 2012
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (4) , 579-587
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Before these trials were done, the effects of CYP3A4 inhibition and induction on the pharmacokinetics (PK) and pharmacodynamics (PD) of tolvaptan in healthy subjects were unknown. As tolvaptan is a CYP3A4 substrate, knowing the effects of inhibition and induction on CYP3A4‐mediated metabolism was important for dosing recommendations.WHAT THIS STUDY ADDS• This paper describes the changes in tolvaptan PK and PD following inhibition or induction of CYP3A4 and explores the mechanisms behind the disparity seen between tolvaptan PK and effects on urine output. It also discusses the concentrations at which tolvaptan produces its maximal response on urine output and the timing of the onset and offset of this response.AIMSIn vitrostudies indicated CYP3A4 alone was responsible for tolvaptan metabolism. To determine the effect of a CYP3A4 inhibitor (ketoconazole) and a CYP3A4 inducer (rifampicin) on tolvaptan pharmacokinetics (PK) and pharmacodynamics (PD), two clinical trials were performed.METHODSFor CYP3A4 inhibition, a double‐blind, randomized (5:1), placebo‐controlled trial was conducted in 24 healthy subjects given either a single 30 mg dose of tolvaptan (n= 19) or matching placebo (n= 5) on day 1 with a 72 h washout followed by a 3 day regimen of 200 mg ketoconazole, once daily with 30 mg tolvaptan or placebo also given on day 5. For CYP3A4 induction, 14 healthy subjects were given a single dose of 240 mg tolvaptan with 48 h washout followed by a 7 day regimen of 600 mg rifampicin, once daily, with 240 mg tolvaptan also given on the seventh day.RESULTSWhen co‐administered with ketoconazole, meanCmaxand AUC(0,∞) of tolvaptan were increased 3.48‐ and 5.40‐fold, respectively. Twenty‐four hour urine volume increased from 5.9 to 7.7 l. Erythromycin breath testing showed no difference following a single dose of tolvaptan. With rifampicin, tolvaptan meanCmaxand AUC were reduced to 0.13‐ and 0.17‐fold of tolvaptan administered alone. Twenty‐four hour urine volume decreased from 12.3 to 8.8 l.CONCLUSIONSTolvaptan is a sensitive CYP3A4 substrate with no inhibitory activity. Due to the saturable nature of tolvaptan's effect on urine excretion rate, changes in the pharmacokinetic profile of tolvaptan do not produce proportional changes in urine output.Keywords
This publication has 18 references indexed in Scilit:
- In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy SubjectsThe Journal of Clinical Pharmacology, 2011
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazoleClinical Pharmacology & Therapeutics, 1999
- Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*Clinical Pharmacology & Therapeutics, 1999
- OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in RatsThe Journal of Pharmacology and Experimental Therapeutics, 1998
- Predicting Drug Interactions In Vivo from Experiments In VitroAmerican Journal of Clinical Oncology, 1997
- HYPONATREMIA AND HYPERNATREMIAMedical Clinics of North America, 1997
- Pathophysiology of the Aquaporin Water ChannelsAnnual Review of Physiology, 1996
- Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath testClinical Pharmacology & Therapeutics, 1994
- Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.Journal of Clinical Investigation, 1989